
South African Health Products Regulatory Authority (SAHPRA) has approved the sweet-tasting, heat-stable and '4-in-1' fixed-dose combination of four antiretroviral (ARV) treatments composed of abacavir, lamivudine, lopinavir, and ritonavir that is specifically designed for infants and young children with HIV, Cipla said in a regulatory filing.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/GtD3HTZ
via
IFTTT
0 comments:
Post a Comment